A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
Public ClinicalTrials.gov record NCT02657434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in two phases: Induction Phase and Maintenance Phase.
Study identification
- NCT ID
- NCT02657434
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 578 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2016 (Actual)
- Primary completion
- Jul 18, 2019 (Actual)
- Completion
- Dec 13, 2022 (Actual)
- Last update posted
- Nov 21, 2023
2016 – 2022
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles Hematology Oncology Medical Group | Los Angeles | California | 90017 | — |
| St. Joseph Heritage Healthcare | Sebastopol | California | 95472 | — |
| Stamford Hospital; BCC, MOHR | Stamford | Connecticut | 06904 | — |
| Orlando Health Inc. | Orlando | Florida | 32806 | — |
| Tallahassee Memorial Hospital | Tallahassee | Florida | 32308 | — |
| Northside Hospital | Atlanta | Georgia | 30342 | — |
| Ingalls Memorial Hospital | Harvey | Illinois | 60426 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| HealthCare Research Network II, LLC - PPDS | Tinley Park | Illinois | 60487 | — |
| Fort Wayne Med Oncology & Hematology Inc | Fort Wayne | Indiana | 46845 | — |
| Goshen Health System | Goshen | Indiana | 46526 | — |
| University of Kentucky; Markey Cancer Center | Lexington | Kentucky | 40536 | — |
| University of Michigan | Ann Arbor | Michigan | 48109-0934 | — |
| CHI Health St. Francis | Grand Island | Nebraska | 68803 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Swedish Cancer Institute | Cary | North Carolina | 27513 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| Allegheny Cancer Center | Pittsburgh | Pennsylvania | 15212 | — |
| Oncology Consultants PA | Houston | Texas | 77030 | — |
| Virginia Cancer Specialists (Fairfax) - USOR | Fairfax | Virginia | 22031 | — |
| Peninsula Cancer Institute | Newport News | Virginia | 23601 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | — |
| University of Washington | Seattle | Washington | 98195 | — |
| St. Vincent Hospital | Green Bay | Wisconsin | 54311 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02657434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02657434 live on ClinicalTrials.gov.